Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | F2 | P00734 | 2/20 | 0.45 |
| ▸ | ELANE | P08246 | 2/20 | 0.45 |
| ▸ | CTSG | P08311 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | PREP | P48147 | 2/20 | 0.45 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1694386 | 1.00 | SMN1; SMN2 (0.50) | SMN1; SMN2NPC1RAB9ACYP2C19F2 | |
| SCHEMBL1694387 | 1.00 | SMN1; SMN2 (0.50) | SMN1; SMN2NPC1RAB9ACYP2C19F2 | |
| SCHEMBL4186350 | 0.88 | SMN1; SMN2 (0.56) | SMN1; SMN2NPC1RAB9ACYP2C19F2 | |
| SCHEMBL4186357 | 0.88 | SMN1; SMN2 (0.56) | SMN1; SMN2NPC1RAB9ACYP2C19F2 | |
| SCHEMBL6252758 | 0.88 | SMN1; SMN2 (0.56) | SMN1; SMN2NPC1RAB9ACYP2C19F2 | |
| SCHEMBL12164616 | 0.87 | POLB (0.55) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL14012812 | 0.87 | POLB (0.55) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL8660402 | 0.87 | POLB (0.55) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL8697857 | 0.87 | POLB (0.55) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL3578965 | 0.87 | POLB (0.55) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8796256-B2 | Substituted thiazolidinedione indazoles, indoles and benzotriazoles as estrogen-related receptor-α modulators | JANSSEN PHARMACEUTICA NV (BE) | 2014-08-05 | — | — | US | disclosed |
| WO-2011149841-A1 | SUBSTITUTED THIAZOLIDINEDIONE INDAZOLES, INDOLES AND BENZOTRIAZOLES AS ESTROGEN-RELATED RECEPTOR-α MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-12-01 | — | — | WO | disclosed |
| US-20110294780-A1 | SUBSTITUTED THIAZOLIDINEDIONE INDAZOLES, INDOLES AND BENZOTRIAZOLES AS ESTROGEN-RELATED RECEPTOR-a MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294780-A1 | SUBSTITUTED THIAZOLIDINEDIONE INDAZOLES, INDOLES AND BENZOTRIAZOLES AS ESTROGEN-RELATED RECEPTOR-a MODULATORS | ESR2, IGF1R, ESRRA | SMN1; SMN2 3467/4885NPC1 2224/4885RAB9A 3774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.